Targeted Fusion Biopsy of the Prostate

Completed · Phase 2

Conditions studied: Prostatic Neoplasms

In brief

The purpose of this study is to see if using Positron Emission Tomography (PET) scan and transrectal ultrasound (TRUS) guided biopsy together (creating a 3-dimensional ultrasound) will detect prostate cancer more accurately than the standard 2-dimensional approach which uses only the TRUS to guide the biopsy.

Key facts

Study ID

NCT02744534

Run by

Emory University

People needed

21

Starts

2015-11-01

Expected to finish

2018-03-31

Last updated by the study team

2019-05-08

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Have been originally diagnosed with prostate carcinoma and have undergone definitive non-prostatectomy therapy for localized disease
• There is suspicion of recurrent prostate carcinoma as defined by: Older American Society for Radiation Oncology (ASTRO) criteria of three consecutive rises of prostate-specific antigen (PSA) or earlier if clinically appropriate, and/or nadir + 2.0 ng/ml (Radiation Therapy Oncology Group (RTOG)-ASTRO Phoenix criteria)
• Able to provide written informed consent

You may not qualify if…

• Cryotherapy, external beam radiation, or high intensity focused ultrasound (HIFU) within the past year
• Brachytherapy within the past two years (to rule out a transient rise in PSA)
• Prostate biopsy within the past month (to decrease a false positive result due to inflammation)
• Not otherwise eligible for prostate biopsy

Where it is running

• Emory University Hospital — Atlanta, Georgia, United States
• Emory University Winship Cancer Institute — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.